Long-term exposure to oral methylphenidate or dl-amphetamine mixture in peri-adolescent rhesus monkeys: Effects on physiology, behavior, and dopamine system development

Neuropsychopharmacology

Volumn 37, Issue 12, 2012, Pages 2566-2579

  Soto, Paul L ^a   Wilcox, Kristin M ^a   Zhou, Yun ^a   Ator, Nancy A ^a   Riddle, Mark A ^a   Wong, Dean F ^a,b,c   Weed, Michael R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

ADHD; amphetamine; CANTAB; methylphenidate; monkey; PET

Indexed keywords

AMPHETAMINE; CLASTOGEN; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; METHYLPHENIDATE;

ADOLESCENT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING KINETICS; BIOLOGICAL MONITORING; BLOOD SAMPLING; BODY WEIGHT; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; CROWN RUMP LENGTH; CYTOGENETICS; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EXPOSURE; EXECUTIVE FUNCTION; HABITUATION; HEAD CIRCUMFERENCE; INHIBITION KINETICS; LONG TERM CARE; MALE; NEUROCHEMISTRY; NEUROIMAGING; NONHUMAN; PERIPHERAL LYMPHOCYTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RESPONSE TIME; RHESUS MONKEY; TASK PERFORMANCE;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMOSOME ABERRATIONS; DATA INTERPRETATION, STATISTICAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EXECUTIVE FUNCTION; GROWTH; MACACA MULATTA; MALE; METHYLPHENIDATE; MOTOR ACTIVITY; NERVOUS SYSTEM; POSITRON-EMISSION TOMOGRAPHY; REACTION TIME; RECEPTORS, DOPAMINE D2; SELF ADMINISTRATION; SISTER CHROMATID EXCHANGE;

EID: 84867581296     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.119     Document Type: Article

References (60)

1. Baldwin RL, Chelonis JJ, Flake RA, Edwards MC, Feild CR, Meaux JB et al (2004). Effect of methylphenidate on time perception in children with attention-deficit/hyperactivity disorder. Exp Clin Psychopharmacol 12: 57-64.
2. Brown GL, Ebert MH, Hunt RD (1978). Plasma d-amphetamine absorption and elimination in hyperactive children. Psychopharmacol Bull 14: 33-35.
3. Castner SA, al-Tikriti MS, Baldwin RM, Seibyl JP, Innis RB, Goldman-Rakic PS (2000). Behavioral changes and [123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine. Neuropsychopharmacology 22: 4-13.
4. Cohen-Zion M, Ancoli-Israel S (2004). Sleep in children with attentiondeficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies. Sleep Med Rev 8: 379-402.
5. de Jong HW, van Velden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA (2007). Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol 52: 1505-1526.
6. Decamp E, Schneider JS (2004). Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Eur J Neurosci 20: 1371-1378.
7. Dias R, Robbins TW, Roberts AC (1996). Primate analogue of the Wisconsin Card Sorting Test: effects of excitotoxic lesions of the prefrontal cortex in the marmoset. Behav Neurosci 110: 872-886.
8. Efron D, Jarman F, Barker M (1997). Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 100: 662-666.
9. El-Zein RA, Abdel-Rahman SZ, Hay MJ, Lopez MS, Bondy ML, Morris DL et al (2005). Cytogenetic effects in children treated with methylphenidate. Cancer Lett 230: 284-291.
10. Ginovart N, Farde L, Halldin C, Swahn CG (1999). Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 31: 154-162.
11. Gray RA, Wilcox KM, Zink MC, Weed MR (2006). Impaired performance on the object retrieval-detour test of executive function in the SIV/macaque model of AIDS. AIDS Res Hum Retroviruses 22: 1031-1035.
12. Greenhill LL, Swanson JM, Steinhoff K, Fried J, Posner K, Lerner M et al (2003). A pharmacokinetic/pharmacodynamic study comparing a single morning dose of Adderall to twice-daily dosing in children with ADHD. J Am Acad Child Adolesc Psychiatry 42: 1234-1241.
13. Guilarte TR, Chen MK, McGlothan JL, Verina T, Wong DF, Zhou Y et al (2006). Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol 202: 381-390.
14. Haber SN (2003). The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat 26: 317-330.
15. Horti AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP et al (2006). 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med 47: 1689-1696.
16. Ibrahim el SR (2002). Rates of adherence to pharmacological treatment among children and adolescents with attention deficit hyperactivity disorder. Hum Psychopharmacol 17: 225-231.
17. Jentsch JD, Roth RH, Taylor JR (2000). Object retrieval/detour deficits in monkeys produced by prior subchronic phencyclidine administration: evidence for cognitive impulsivity. Biol Psychiatry 48: 415-424.
18. Kempton S, Vance A, Maruff P, Luk E, Costin J, Pantelis C (1999). Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children. Psychol Med 29: 527-538.
19. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. NeuroImage 4(Part 1): 153-158.
20. Mattes JA, Gittelman R (1983). Growth of hyperactive children on maintenance regimen of methylphenidate. Arch Gen Psychiatry 40: 317-321.
21. Mattison DR, Plant TM, Lin HM, Chen HC, Chen JJ, Twaddle NC et al (2011). Pubertal delay in male nonhuman primates (Macaca mulatta) treated with methylphenidate. Proc Natl Acad Sci USA 108: 16301-16306.
22. Mehta MA, Goodyer IM, Sahakian BJ (2004). Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry 45: 293-305.
23. Middleton FA, Strick PL (2002). Basal-ganglia 'projections' to the prefrontal cortex of the primate. Cereb Cortex 12: 926-935.
24. Morris SM, Dobrovolsky VN, Shaddock JG, Mittelstaedt RA, Bishop ME, Manjanatha MG et al (2009). The genetic toxicology of methylphenidate hydrochloride in non-human primates. Mutat Res 673: 59-66.
25. Morris SM, Petibone DM, Lin WJ, Chen JJ, Vitiello B, Witt KL et al (2012). The genetic toxicity of methylphenidate: a review of the current literature. J Appl Toxicol; e-pub ahead of print 15 February 2012.
26. Mostofsky SH, Cooper KL, Kates WR, Denckla MB, Kaufmann WE (2002). Smaller prefrontal and premotor volumes in boys with attention-deficit/ hyperactivity disorder. Biol Psychiatry 52: 785-794.
27. MTA Cooperative Group (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56: 1073-1086.
28. MTA Cooperative Group (2004a). National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/ hyperactivity disorder. Pediatrics 113: 754-761.
29. MTA Cooperative Group (2004b). National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113: 762-769.
30. Norman A, Cochran ST, Sayre JW (2001). Meta-analysis of increases in micronuclei in peripheral blood lymphocytes after angiography or excretory urography. Radiat Res 155: 740-743.
31. Patrick KS, Markowitz JS (1997). Pharmacology of methlyphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol 12: 527-546.
32. Ponsa I, Ramos-Quiroga JA, Ribases M, Bosch R, Bielsa A, Ordeig MT et al (2009). Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate. Mutat Res 666: 44-49.
33. Poulton A, Cowell CT (2003). Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health 39: 180-185.
34. Rahmim A, Cheng JC, Blinder S, Camborde ML, Sossi V (2005). Statistical dynamic image reconstruction in state-of-the-art high-resolution PET. Phys Med Biol 50: 4887-4912.
35. Rapport MD, Moffitt C (2002). Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 22: 1107-1131.
36. Rawlins RG, Kessler MJ, Turnquist JE (1984). Reproductive performance, population dynamics and anthropometrics of the free-ranging Cayo Santiago rhesus macaques. J Med Primatol 13: 247-259.
37. Robinson TE, Becker JB (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396: 157-198.
38. Rodriguez JS, Morris SM, Hotchkiss CE, Doerge DR, Allen RR, Mattison DR et al (2010). The effects of chronic methylphenidate administration on operant test battery performance in juvenile rhesus monkeys. Neurotoxicol Teratol 32: 142-151.
39. Rutten K, Basile JL, Prickaerts J, Blokland A, Vivian JA (2008). Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology (Berl) 196: 643-648.
40. Segal DS, Geyer MA, Schuckit MA (1981). Stimulant-induced psychosis: an evaluation of animal methods. Essays Neurochem Neuropharmacol 5: 95-129.
41. Sossi V, de Jong HWAM, Barker WC, Bloomfield P, Burbar Z, Camborde M-L et al (2005). The second-generation HRRTFa multi-centre scanner performance investigation. Nucl Sci Symp Conf Record 4: 2195-2199.
42. Sowell ER, Thompson PM, Welcome SE, Henkenius AL, Toga AW, Peterson BS (2003). Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet 362: 1699-1707.
43. Spear J, Alderton D (2003). Psychosis associated with prescribed dexamphetamine use. Aust N Z J Psychiatry 37: 383.
44. Spruyt K, Gozal D (2011). Sleep disturbances in children with attention-deficit/hyperactivity disorder. Expert Rev Neurother 11: 565-577.
45. Swanson JM, Volkow ND (2003). Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev 27: 615-621.
46. Tannock R, Schachar RJ, Carr RP, Chajczyk D, Logan GD (1989). Effects of methylphenidate on inhibitory control in hyperactive children. J Abnorm Child Psychol 17: 473-491.
47. Tucker JD, Suter W, Petibone DM, Thomas RA, Bailey NL, Zhou Y et al (2009). Cytogenetic assessment of methylphenidate treatment in pediatric patients treated for attention deficit hyperactivity disorder. Mutat Res 677: 53-58.
48. Tulloch SJ, Zhang Y, McLean A, Wolf KN (2002). SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy 22: 1405-1415.
49. Vles JS, Feron FJ, Hendriksen JG, Jolles J, van Kroonenburgh MJ, Weber WE (2003). Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics 34: 77-80.
50. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS et al (1998). Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155: 1325-1331.
51. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R et al (1997). Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386: 830-833.
52. Weed MR, Bryant R, Perry S (2008a). Cognitive development in macaques: attentional set-shifting in juvenile and adult rhesus monkeys. Neuroscience 157: 22-28.
53. Weed MR, Hienz RD (2006). Effects of morphine on circadian rhythms of motor activity and body temperature in pig-tailed macaques. Pharmacol Biochem Behav 84: 487-496.
54. Weed MR, Hienz RD, Brady JV, Adams RJ, Mankowski JL, Clements JE et al (2003). Central nervous system correlates of behavioral deficits following simian immunodeficiency virus infection. J Neurovirol 9: 452-464.
55. Weed MR, Taffe MA, Polis I, Roberts AC, Robbins TW, Koob GF et al (1999). Performance norms for a rhesus monkey neuropsychological testing battery: acquisition and long-term performance. Brain Res Cogn Brain Res 8: 185-201.
56. Weed MR, Wilcox KM, Ator NA, Hienz RD (2008b). Consistent, high-level ethanol consumption in pig-tailed macaques via a multiple-session, limited-intake, oral self-dosing procedure. Alcohol Clin Exp Res 32: 942-951.
57. Wilcox KM, Zhou Y, Wong DF, Alexander M, Rahmim A, Hilton J et al (2008). Blood levels and DA transporter occupancy of orally administered methylphenidate in juvenile rhesus monkeys measured by high resolution PET. Synapse 62: 950-952.
58. Williamson S, Gossop M, Powis B, Griffiths P, Fountain J, Strang J (1997). Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend 44: 87-94.
59. Witt KL, Shelby MD, Itchon-Ramos N, Faircloth M, Kissling GE, Chrisman AK et al (2008). Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD. J Am Acad Child Adolesc Psychiatry 47: 1375-1383.
60. Zhou Y, Chen MK, Endres CJ, Ye W, Brasic JR, Alexander M et al (2006). An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge. NeuroImage 33: 550-563.